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Abstract  
Haematocrit is known to influence glucose values obtained on some blood 
glucose meters, with bias observed especially at low and high haematocrit 
levels.  We evaluated the performance of a meter with haematocrit correction 
technology alongside 3 other commercially available meters. Capillary blood 
samples from 100 subjects were analysed in duplicate and compared to the 
plasma values obtained by reference laboratory analyser. Bias, error grid and 
sensitivity to haematocrit analyses were performed for each meter. Average 
percentage bias was similar for all meters, however the evaluated meter 
performed best with respect to error grid analysis, with 100% of values falling 
within the ‘no effect on clinical action’ and ‘no risk’ categories and did not 
display any haematocrit associated bias.  
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Introduction 
Diabetes is a chronic condition, affecting approximately 425 million people 
globally [1]. Achieving tight glucose control in people with diabetes has been 
shown to reduce the development of a number of diabetes-associated 
complications [2]. Self-monitoring of blood glucose (SMBG) provides a means 
to improve the glycaemic control of a person with diabetes, in addition to 
identifying hypoglycaemic events in those on insulin therapy [3]. 
The guidelines for determining system accuracy on blood glucose meters (BS 
EN ISO 15197:2015) [4] state that accuracy should be determined from at least 
100 different subjects, and evaluated under actual conditions of use to include 
the effects of both systematic error (measurement bias) and random error 
(measurement imprecision). The system accuracy evaluation should be 
performed on fresh blood samples, at least in duplicate and compared to 
reference laboratory glucose concentrations, both pre- and post-
measurement with the glucose meter.  
Haematocrit has previously been shown to demonstrate considerable 
influence on the glucose readings obtained from certain blood glucose 
monitors, even when tested within the manufacturer’s recommended 
haematocrit range [5, 6]. Typically, a positive bias is observed at low 
haematocrit levels and a negative bias at higher haematocrit levels [7 - 9]. In 
this study, the system accuracy of the evaluated blood glucose meter, the 
GlucoRx HCT meter (GlucoRx, Surrey, UK), that utilises a novel haematocrit 
correction technology, was compared to 3 other blood glucose meters used in 
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the UK across a wide range of blood glucose concentrations, similar to that 
specified in Section 8 BS ISO 15197:2015 [4]. 
Methods 
This study was performed between March and April 2018 at the Joint Clinical 
Research Facility, ILS2, Swansea University, Swansea, UK, in compliance with 
Good Clinical Practice and was approved by Wales REC 6 (18/WA/0023) prior 
to commencement of the study.   
Subjects 
A total of 114 participants were recruited to achieve 100 full, evaluable 
datasets. Subjects with diabetes mellitus (type 1 and type 2) and without 
diabetes were included in the study, and on entry were all aged ≥ 18 years old. 
Informed, signed consent was received from all participants. 
Blood Glucose Monitoring Systems 
The evaluated meter (Meter A) is a multiparameter meter, capable of 
measuring blood glucose, ketones and haematocrit. The meter uses advanced 
GDH-FAD enzyme technology with an AC signal which provides the 
haematocrit result, and DC signal which calculates glucose. The meter then 
modulates the glucose level according to the haematocrit value allowing 
enhanced accuracy in measurement of glucose.  Meter A was compared to 
three other meters (Meters B, C and D - in no particular order); these included 
the Roche Accu-chek Aviva (Roche Diagnostics Ltd., West Sussex, UK) which 
measures blood glucose only, and two dual glucose and ketone meters; 
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Caresens Dual BGM System (distributed by Spirit Healthcare, Leicester, UK) 
and Menarini GlucoMen Areo 2K (A Menrini Diagnostics, Berkshire, UK). 
Meters B, C and D were selected for this study due to their availability and 
current use within the UK. For this study, the ketone function was not used on 
the dual systems. All meters and strips were purchased directly by the research 
team and were not provided by the manufacturers. 
Study Procedure 
Procedures performed were similar to those outlined in EN ISO 15197:2015. 
Briefly, eligible subjects had a fingerprick performed using a high flow lancet. 
Capillary blood (approximately 100ul) was collected into lithium heparin 
anticoagulant (Microvette, Sarstedt, Leicester, UK), with the sample used for 
determination of plasma glucose on the reference laboratory glucose analyser. 
Following this, duplicate blood glucose measurements were performed on the 
4 blood glucose meters in a random order, before a second reference glucose 
sample was collected. Finally, haematocrit was determined. For the reference 
YSI measurement, the Microvette tubes were centrifuged within 5 minutes of 
collection and the plasma glucose determined. A total of approximately 250ul 
was collected from each participant. 
Of the 100 eligible samples, a total of 20 modified samples were included to 
allow determination of sufficient numbers of low (by glycolysis) and high (by 
addition of glucose solution) glucose concentrations.  
Laboratory Measurements 
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The reference laboratory plasma glucose was determined using a YSI 2300 Stat 
Plus (Yellow Springs Instruments, Fleet, UK). Daily internal quality control was 
performed before any study samples were run (Assayed Chemistry Control 
Plus, levels 2 and 3, Randox, UK). Microvette tubes were centrifuged within 5 
minutes of collection and the plasma component used for glucose 
determination. 
Haematocrit was determined using a HemoControl analyser (EKF Diagnostics, 
Cardiff, UK) 
Data Analysis 
Data were excluded from analysis if the reference laboratory measurements 
differed by >4% at glucose concentrations <100mg/dL or >4mg/dL at glucose 
concentrations ≥100mg/dL, if valid glucose readings were not obtained on all 
meters or if insufficient sample volume was available for all measurements to 
be performed. 
Accuracy for each meter was assessed according to the number of readings 
within 5, 10 and 15mg/dL (glucose <100 mg/dL) or 5, 10 and 15% (glucose 
≥mg/dL) of the reference glucose value and the accuracy for each individual 
meter compared using the Cochran-Mantel-Haenszel test. Bias plots, Parkes 
Consensus Error Grids (CEG) [10] and Surveillance Error Grids (SEG) [11] were 
performed for each meter. In addition, sensitivity of the individual meters to 
haematocrit was assessed by regression analysis of the relative glucose 
differences (meter and reference glucose) versus haematocrit.  
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Results 
The batches of meters and strips used were:  
Meters 4279317350041211 / 4279317350041299; Strips TD17G110-BHF 
Meters 45900007291 / 45900013602 / 45900019971; Strips 497275 
Meters F024073F0910 / F024073F0906; Strips PJ25CAQ1B 
Meters GT168145 / GT168206; Strips HS170705. 
 
For the 100 evaluated samples, the observed glucose range determined on the 
reference analyser was 33 to 581mg/dL and haematocrit was 28 – 50%.  
The average percentage bias between the meters and reference glucose 
measurement were 5.3, 5.0, 5.9 and 6.6%; meters A to D respectively (Figure 
1).  
For meters A to D respectively, 99.5, 98.0, 96.0 and 96.0% of the meter values 
were within ±15mg/dL (glucose <100mg/dL) or ±15% (glucose ≥100mg/dL) of 
the reference glucose value (Table 1), with meter A displaying significantly 
greater accuracy when compared to both meters C and D (P=0.044 and 0.043 
respectively). 
Error Grid Analysis 
For meter A, 100% of glucose values fell within Zone A (no effect on clinical 
action) and were classed as ‘no risk’ on the CEG and SEG plots respectively.  For 
the remainder of the meters, the corresponding values were 100% and 97.5% 
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(meter B), 99.5% and 98.5% (meter C) and 98.0% and  96.5% (meter D) (Table 
2 and Figures 2 and 3).  
Sensitivity to Haematocrit 
The haematocrit values of the samples tested were within the accepted ranges 
for all meters. Across an increasing haematocrit range, the magnitude of 
spread of relative glucose differences (reference and meter) remained 
relatively constant for meters A, B and C, however greater variation was 
observed for meter D (Figures 4 and 5). Neither the slope nor intercept of the 
calculated regression lines differed from zero for meters A or D but were 
significantly different for both meters B and C (all P<0.01). 
Discussion 
In this study, the performance of a blood glucose meter with novel 
haematocrit correction technology (meter A) was evaluated and compared to 
the performance of three commercially available blood glucose monitoring 
systems across a wide glucose concentration range, based on the guidelines 
stated in Section 8 BS ISO 15197:2015. One of the limitations of this study is 
that while the latest ISO guidelines were followed in terms of number of 
samples and glucose concentration range tested, only a single batch of test 
strips was employed. The three comparator meters (B to D) were selected due 
to their availability and usage within the UK.  
The accuracy of readings generated by blood glucose meters is essential to 
ensure both tight glucose control and patient safety, as such the International 
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Organisation for Standardisation (ISO) has published guidelines to evaluate 
blood glucose meters. According to the most recent recommendations (ISO 
15197:2015), 95% of meter readings should be within ±15mg/dL (for glucose 
concentrations <100mg/dL) or ±15% (glucose concentrations ≥100mg/dL) of 
the reference glucose concentrations. In this study, all meters were found to 
achieve these targets, ranging from 99.5% (meter A) to 96.0% (meters C and 
D).   
With respect to the CEG and SEG scores the evaluated meter (meter A) 
performed the best with all results in zone A (no effect on clinical outcome - 
CEG) or ‘no risk’ (SEG). Meter D was more variable with 1 % of values falling in 
Zone C (leading to unnecessary treatment –CEG) and ‘moderate, lower risk’ 
(SEG). 
The magnitude of the relative glucose differences between meter and 
reference glucose was similar across the tested haematocrit range for meters 
A, B and C, but showed greater variation for meter D. However, despite this 
similarity in magnitude of spread for meters A, B and C, the meter A was the 
only one that did not display haematocrit associated bias.  
Conclusions 
In this study, the performance of all the blood glucose meters was within ISO 
15197:2015 guidelines, meter A had the best performance due to the 
haematocrit correction technology employed within this meter.  
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Tables and table legends: 
Table 1 Accuracy results 
 Glucose <100mg/dL Glucose ≥100mg/dL Combined 
±15mg/Dl 
OR  ±15% 
 ±5mg/dL ±10mg/dL ±15mg/dL ±5% ±10% ±15% 
Meter A 48/60 
80.0% 
56/60 
93.3% 
59/60 
98.3% 
72/140 
51.4% 
129/140 
92.1% 
140/140 
100.0% 
199/200 
99.5% 
Meter B 38/60 
63.3% 
56/60 
93.3% 
58/60 
96.7% 
90/140 
64.3% 
129/140 
92.1% 
138/140 
98.6% 
196/200 
98.0% 
Meter C 35/60 
58.3% 
56/60 
93.3% 
58/60 
96.7% 
74/140 
52.9% 
118/140 
84.3% 
134/140 
95.7% 
192/200 
96.0% 
Meter D 21/60 
35.0% 
45/60 
75.0% 
55/60 
91.7% 
77/140 
55.0% 
122/140 
87.1% 
137/140 
97.9% 
192/200 
96.0% 
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Table 2 Error Grid analysis 
 Consensus Error Grid (CEG) Zone Surveillance Error Grid Degree of Risk 
 A B C D E None Slight, 
Lower 
Slight, 
Higher 
Moderate, 
Lower 
Moderate, 
Higher 
Great, 
Lower 
Great, 
Higher 
Extreme 
Meter A 200 
100.0% 
- - - - 200 
100.0% 
- - - - - - - 
Meter B 200 
100.0% 
- - - - 195 
97.5% 
5 
2.50% 
- - - - - - 
Meter C 199 
99.5% 
1 
0.5% 
- - - 197 
98.5% 
3 
1.5% 
- - - - - - 
Meter D 194 
98.0% 
2 
1.0% 
2 
1.0% 
- - 193 
96.5% 
5 
2.5% 
- 2 
1.0% 
- - - - 
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Figures and figure legends: 
 
Figure 1 Bias plots; Meter A, B, C and D 
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Figure 2 Consensus Error Grids; Meter A, B, C and D 
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Figure 3 Surveillance Error Grids; Meter A, B, C and D 
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Figure 4 Relative difference between meter and YSI according to 
haematocrit; Meter A, B, C and D 
 
 
Figure 5 Expanded view of the relative difference between meter and 
YSI according to haematocrit; Meter A, B, C and D 
 
 
 
